Lambert W E, Meyer E, De Leenheer A P, De Bersaques J, Kint A H
Laboratoria voor Medische Biochemie en voor Klinische Analyse, Universiteit Gent, Belgium.
J Am Acad Dermatol. 1992 Dec;27(6 Pt 2):S19-22. doi: 10.1016/s0190-9622(08)80255-1.
Acitretin, the metabolite of etretinate, is eliminated far more rapidly from the human body than is etretinate. It had therefore been suggested that only a short period of contraception would be required after the cessation of long-term therapy with acitretin. However, recent studies have demonstrated the presence of etretinate in the plasma of patients who were treated with acitretin. In this article we provide results from a study in our center and discuss earlier data in light of the recently discovered metabolic pathways for acitretin. Reesterification of acitretin to etretinate, however, results in a loss of the metabolic advantages of acitretin. Because of this situation the recommended contraception period after acitretin therapy has been lengthened to 2 years.
阿维A是依曲替酯的代谢产物,其从人体中清除的速度比依曲替酯快得多。因此,有人提出,在停止长期使用阿维A治疗后,只需进行短时间的避孕。然而,最近的研究表明,接受阿维A治疗的患者血浆中存在依曲替酯。在本文中,我们提供了我们中心一项研究的结果,并根据最近发现的阿维A代谢途径讨论了早期数据。然而,阿维A重新酯化为依曲替酯会导致阿维A代谢优势的丧失。由于这种情况,阿维A治疗后推荐的避孕期已延长至2年。